INT8803

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1990
Last Reported 2010
Negated 2
Speculated 1
Reported most in Abstract
Documents 32
Total Number 33
Disease Relevance 21.06
Pain Relevance 6.01

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IL3) extracellular region (IL3) cell-cell signaling (IL3)
Anatomy Link Frequency
bone marrow 5
eosinophils 3
macrophage 2
leukocyte 2
neutrophils 2
IL3 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 179 100.00 Very High Very High Very High
Inflammation 134 100.00 Very High Very High Very High
chemokine 36 100.00 Very High Very High Very High
Inflammatory mediators 13 99.96 Very High Very High Very High
Angina 6 99.02 Very High Very High Very High
Inflammatory marker 3 96.20 Very High Very High Very High
headache 21 96.04 Very High Very High Very High
metalloproteinase 7 95.72 Very High Very High Very High
Chronic pancreatitis 4 93.16 High High
corticosteroid 15 93.00 High High
Disease Link Frequency Relevance Heat
INFLAMMATION 152 100.00 Very High Very High Very High
Hematological Disease 11 100.00 Very High Very High Very High
Myelodysplastic Syndromes 7 100.00 Very High Very High Very High
Apoptosis 84 99.84 Very High Very High Very High
Pancreatic Cancer 14 99.60 Very High Very High Very High
Myocardial Infarction 10 99.24 Very High Very High Very High
Increased Venous Pressure Under Development 15 99.06 Very High Very High Very High
Angina 6 99.02 Very High Very High Very High
Emergencies 2 98.00 Very High Very High Very High
Recurrence 3 97.92 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Phase I/II trials with recombinant human IL-3 (rhIL-3) expressed in yeast are being done in patients with advanced malignancies as well as in patients with bone marrow failure states.
Gene_expression (expressed) of IL-3 in bone marrow
1) Confidence 0.78 Published 1991 Journal Am. J. Clin. Oncol. Section Abstract Doc Link 2048566 Disease Relevance 0.06 Pain Relevance 0
Phase I/II trials with recombinant human IL-3 (rhIL-3) expressed in yeast are being done in patients with advanced malignancies as well as in patients with bone marrow failure states.
Gene_expression (expressed) of rhIL-3 in bone marrow
2) Confidence 0.78 Published 1991 Journal Am. J. Clin. Oncol. Section Abstract Doc Link 2048566 Disease Relevance 0.06 Pain Relevance 0
Recombinant human interleukin 3 (rhIL-3, expressed in Escherichia coli) is a hematopoietic growth factor with protean biological effects on bone marrow in animal models, including enhanced granulocyte and platelet production and the capacity to ameliorate chemotherapy-induced bone marrow toxicity.
Gene_expression (expressed) of rhIL-3 in bone marrow associated with toxicity
3) Confidence 0.77 Published 1995 Journal Clin. Cancer Res. Section Abstract Doc Link 9815905 Disease Relevance 0.24 Pain Relevance 0
Recombinant human interleukin 3 (rhIL-3, expressed in Escherichia coli) is a hematopoietic growth factor with protean biological effects on bone marrow in animal models, including enhanced granulocyte and platelet production and the capacity to ameliorate chemotherapy-induced bone marrow toxicity.
Gene_expression (expressed) of interleukin 3 in bone marrow associated with toxicity
4) Confidence 0.77 Published 1995 Journal Clin. Cancer Res. Section Abstract Doc Link 9815905 Disease Relevance 0.24 Pain Relevance 0
Administration of hemopoietic growth factors (HGFs) such as interleukin-3 (IL-3) during chemotherapy may result in an increased cell kill by cytotoxic agents.
Gene_expression (Administration) of IL-3
5) Confidence 0.67 Published 1996 Journal Leukemia Section Abstract Doc Link 8558936 Disease Relevance 0.35 Pain Relevance 0
Administration of hemopoietic growth factors (HGFs) such as interleukin-3 (IL-3) during chemotherapy may result in an increased cell kill by cytotoxic agents.
Gene_expression (Administration) of interleukin-3
6) Confidence 0.67 Published 1996 Journal Leukemia Section Abstract Doc Link 8558936 Disease Relevance 0.35 Pain Relevance 0
Cohorts of five patients received during 7 days 1, 5, 10, or 15 micrograms/kg/d rhIL-3 (days 5 through 11) in cycles 1, 3, and 5 by continuous intravenous (IV) infusion or once daily subcutaneous (SC) administration.
Gene_expression (received) of rhIL-3
7) Confidence 0.67 Published 1992 Journal Blood Section Abstract Doc Link 1515636 Disease Relevance 0.35 Pain Relevance 0
These results suggest that rhIL-3 is effective in stimulating hematopoiesis of all lineages in patients with myelodysplastic syndromes and may produce at least short-term hematologic improvement.
Gene_expression (produce) of rhIL-3 associated with hematological disease and myelodysplastic syndromes
8) Confidence 0.67 Published 1990 Journal Blood Section Abstract Doc Link 2378979 Disease Relevance 0.83 Pain Relevance 0.18
Pharmacokinetic studies were performed in 13 patients, and area under the curve and maximal concentration values increased with increasing rhIL-3 dose levels (P < 0.001) and correlated with maximal changes from baseline in WBC, neutrophils, and eosinophils. rhIL-3 antibodies were detected in 8% of patients by day 29 of cycle 1 but were not neutralizing. rhIL-3 is well tolerated when administered s.c. and has reproducible hematological and immunological effects.
Neg (not) Gene_expression (neutralizing) of rhIL-3 in eosinophils
9) Confidence 0.67 Published 1996 Journal Clin. Cancer Res. Section Abstract Doc Link 9816178 Disease Relevance 0.53 Pain Relevance 0.11
Pharmacokinetic studies were performed in 13 patients, and area under the curve and maximal concentration values increased with increasing rhIL-3 dose levels (P < 0.001) and correlated with maximal changes from baseline in WBC, neutrophils, and eosinophils. rhIL-3 antibodies were detected in 8% of patients by day 29 of cycle 1 but were not neutralizing. rhIL-3 is well tolerated when administered s.c. and has reproducible hematological and immunological effects.
Gene_expression (detected) of rhIL-3 in eosinophils
10) Confidence 0.67 Published 1996 Journal Clin. Cancer Res. Section Abstract Doc Link 9816178 Disease Relevance 0.53 Pain Relevance 0.11
Both cytokines were administered by subcutaneous (SC) bolus injection. rhIL-3/rhGM-CSF treatment was more effective than rhIL-3 but equally effective to each other in increasing peripheral leukocyte counts, especially neutrophilic and eosinophilic granulocyte counts.
Gene_expression (effective) of rhIL-3 in leukocyte associated with rhinitis and cytokine
11) Confidence 0.67 Published 1992 Journal Blood Section Abstract Doc Link 1586711 Disease Relevance 0.41 Pain Relevance 0.09
Both cytokines were administered by subcutaneous (SC) bolus injection. rhIL-3/rhGM-CSF treatment was more effective than rhIL-3 but equally effective to each other in increasing peripheral leukocyte counts, especially neutrophilic and eosinophilic granulocyte counts.
Gene_expression (effective) of rhIL-3 in leukocyte associated with rhinitis and cytokine
12) Confidence 0.67 Published 1992 Journal Blood Section Abstract Doc Link 1586711 Disease Relevance 0.42 Pain Relevance 0.09
Facial flushing developed in 3/8 patients at the highest dose levels of rhIL-3.
Gene_expression (levels) of rhIL-3 associated with increased venous pressure under development
13) Confidence 0.60 Published 1993 Journal Ann. Hematol. Section Abstract Doc Link 8218538 Disease Relevance 0.82 Pain Relevance 0.28
Opposing effects of sodium salicylate and haematopoietic cytokines IL-3, IL-5 and GM-CSF on mitogen-activated protein kinases and apoptosis of EoL-1 cells.
Gene_expression (effects) of IL-3 associated with apoptosis and cytokine
14) Confidence 0.37 Published 1999 Journal Immunol. Invest. Section Title Doc Link 10574634 Disease Relevance 0.71 Pain Relevance 0.35
On the other hand, right branch shows overexpression areas with genes such as CASP 10, CD30-L, and CD-40-L (TNF family), ras-like small, FGF 3 and 5, TDGF1, ERK5, MIF, IFNGR2, MIG, IFN-alpha, beta, gamma, IL-3, -4, -9 and -13, IP-10, HPRT, DCC, TEK, netrin-2, cadherins 4, 8, 12 and 13 [33], MMP3, 8, 10, 12 and 13 (metalloproteinase), COL11A2, CCNG1, CDC-6, ATM, N-MYC, and p53.
Gene_expression (overexpression) of IL-3 in TEK associated with metalloproteinase
15) Confidence 0.26 Published 2005 Journal BMC Cancer Section Body Doc Link PMC1198222 Disease Relevance 0.73 Pain Relevance 0.05
Pharmacokinetic studies were performed in 13 patients, and area under the curve and maximal concentration values increased with increasing rhIL-3 dose levels (P < 0.001) and correlated with maximal changes from baseline in WBC, neutrophils, and eosinophils. rhIL-3 antibodies were detected in 8% of patients by day 29 of cycle 1 but were not neutralizing. rhIL-3 is well tolerated when administered s.c. and has reproducible hematological and immunological effects.
Gene_expression (detected) of rhIL-3 in neutrophils
16) Confidence 0.23 Published 1996 Journal Clin. Cancer Res. Section Abstract Doc Link 9816178 Disease Relevance 0.53 Pain Relevance 0.11
Pharmacokinetic studies were performed in 13 patients, and area under the curve and maximal concentration values increased with increasing rhIL-3 dose levels (P < 0.001) and correlated with maximal changes from baseline in WBC, neutrophils, and eosinophils. rhIL-3 antibodies were detected in 8% of patients by day 29 of cycle 1 but were not neutralizing. rhIL-3 is well tolerated when administered s.c. and has reproducible hematological and immunological effects.
Neg (not) Gene_expression (neutralizing) of rhIL-3 in neutrophils
17) Confidence 0.23 Published 1996 Journal Clin. Cancer Res. Section Abstract Doc Link 9816178 Disease Relevance 0.53 Pain Relevance 0.11
Desreumaux and coworkers detected IL-3, IL-5 and GM-CSF in the duodenal and colonic tissue in 90% of patients with eosinophilic gastroenteritis [38].
Gene_expression (detected) of IL-3 associated with rhinitis and gastroenteritis
18) Confidence 0.17 Published 2004 Journal Clin Mol Allergy Section Body Doc Link PMC425596 Disease Relevance 1.08 Pain Relevance 0.20
In light of existing knowledge on interconnected pathways of pro-inflammatory mediators (leukotrienes, chemokines (IL8, SDF-1 alpha, MIP-1 alpha, MCP-1,2 etc), and cytokines (IL3, IL6, IL12, IL-1 beta, GM-CSF, B94, TNF-alpha etc)), the anti-inflammatory properties of pro-resolving mediators in preventing chronic inflammation which leads to carcinogenesis needs further understanding.
Gene_expression (leukotrienes) of IL3 associated with chemokine, inflammatory mediators, inflammation and cytokine
19) Confidence 0.09 Published 2009 Journal Curr. Mol. Med. Section Abstract Doc Link 19601807 Disease Relevance 0.86 Pain Relevance 0.74
These findings indicate a high degree of proliferation of immune cells; however, there is no significant level of increase in the expression of cytokines like IL-2 or IL-3 and their receptors, which are required for the proliferation and the differentiation of T cells and effector functions of B cells and NK cells.
Gene_expression (expression) of IL-3 in T cells associated with cytokine
20) Confidence 0.08 Published 2005 Journal BMC Immunol Section Body Doc Link PMC546205 Disease Relevance 0.28 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox